Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
allergies
Biotech
Novartis pens $2B deal for biotech with potential Xolair successor
Novartis has penned a $2 billion deal for a biotech whose next-gen anti-IgE program could offer a worthy successor to Xolair.
James Waldron
Mar 27, 2026 4:46am
GSK pays $2.2B to buy Rapt for food allergy challenger to Xolair
Jan 20, 2026 4:37am
Vaccine protects mice from allergic reactions for a year
Apr 17, 2025 1:04pm
BMS backs out of Dupixent fight, axing asset despite phase 3 win
Feb 7, 2025 6:26am
Rapt pays $35M for challenger to Novartis, Roche drug
Dec 23, 2024 8:10am
Holoclara wriggles into ph. 1, sets sights on immune disease
Dec 18, 2024 9:05am
